Home - Products - Others - Other Targets - Clesrovimab

Clesrovimab

CAS No. 2429913-18-6

Clesrovimab( —— )

Catalog No. M36829 CAS No. 2429913-18-6

Clesrovimab (MK1654) is an anti-respiratory syncytial virus protein F human monoclonal antibody for the prevention and treatment of respiratory syncytial virus infections.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	1121	In Stock
10MG	1796	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Clesrovimab
Note

Research use only, not for human use.
Brief Description

Clesrovimab (MK1654) is an anti-respiratory syncytial virus protein F human monoclonal antibody for the prevention and treatment of respiratory syncytial virus infections.
Description

Clesrovimab (MK1654) is a fully human, anti-RSV fusion (RSV F) glycoprotein monoclonal antibody. Clesrovimab has the potential for the research of respiratory syncytial virus infection.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

2429913-18-6
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Qiu X, et al. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 2022 Dec;68:37-53.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

IGS-1.76

IGS-1.76 shows a significantly increased affinity for hNCS-1 and is able to modulate the hNCS-1/Ric8a interaction efficiently.IGS-1.76 efficiently inhibits the human NCS-1/Ric8a complex.IGS-1.76, which efficiently inhibits the human NCS-1/Ric8a complex with improved binding potency.?
Eubulus-A80

Eubulus-A80 is a anti-tumor agent (WO2021/183702, Compound A80).
Relatlimab

Relatlimab(BMS-986016) is a monoclonal antibody targeting human anti-LAG-3, generated by immunization of transgenic mice with human immunoglobulin carrying recombinant LAG-3 protein.

Sign In Join Free